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LETTER TO EDITOR
Long non-coding RNAs are significantly associated with
prognosis and response to therapies in gastric cancer
Dear Editor,
We address the heterogeneity of clinical outcome in gas-
tric cancer (GC) by applying a systems-level characteri-
zation of the long noncoding RNA (lncRNA). We identi-
fied molecular subtypes predictive of response to standard
treatments and demonstrated therapeutic potential of tar-
geting lncRNA for the refractory subtype.
Hierarchical clustering analysis of lncRNA expression
in the The Cancer Genome Atlas (TCGA) stomach adeno-
carcinoma cohort resulted in six distinct clusters, which
were named the LNC6 subtypes (Figure S1A). Owing
to the small sample size and short follow-up period in
the TCGA cohort, prognostic associations of the LNC6
subtypes were evaluated in independent public cohorts
(n = 1,933; Table S1). Because lncRNA expression data
from RNA sequencing are available for only TCGA among
large-scale cohorts, we used LNC6 subtype-specificmRNA
gene signature (Figures 1A and 1B). Bayesian compound
covariate predictor algorithm was adopted to construct a
prediction model,1 and receiver operating characteristic
(ROC) analysis of the predicted probability confirmed its
robustness resulting in area under the ROC curves (AUCs)
greater than 0.9 for all six subtypes (Figure S2). The L6A
andL6F subtypeswere associatedwith poor prognoses, fol-
lowed by the L6B and L6D subtypes, while the L6C and
L6E subtypes were associated with good prognoses (Fig-
ure 1C; see also Table S2 for pairwise comparison results).
LNC6 subtypes also demonstrated differences in clinico-
pathological and molecular characteristics (Table S3; Fig-
ure S3) – notably,more than two-thirds of L6F tumorswere
Lauren diffuse type, while about 5%–10% of L6B and L6C
tumors were diffuse type. In addition, most of L6A and
L6D patients were from Western countries, which might
account for the shrinkage of the two subtypes in the test
cohorts.
ABBREVIATIONS: EP, epithelial phenotype; GC, gastric cancer;
GSEA, gene set enrichment analysis; lncRNAs, long non-coding RNAs;
MP, mesenchymal phenotype; MSI, microsatellite instability; TCGA,
The Cancer Genome Atlas
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We examined the association of LNC6 subtypes with
chemo-response in a merged cohort where about half of
the patients had received standard adjuvant chemotherapy
(Figures 2A and 2B).2,3 Among the major three subtypes
comprising 90% of this cohort, L6B patients exhibited
significant benefit from chemotherapy, while L6C and
L6F patients did not. We also examined the association
of LNC6 subtypes with response to pembrolizumab by
directly analyzing lncRNA expression from the raw RNA
sequencing data of a phase 2 clinical trial (n = 45).4 The
prediction model was constructed based on the expression
data of subtype-specific lncRNAs in the TCGA cohort
(Figure S1B and Table S4). L6C probability was a positive
predictor of clinical response to immune checkpoint block-
ade, whereas L6F probability was a negative predictor
(Figures S4A and S4B). Although the predicted probability
of the L6E subtype could not stratify the responders and
non-responders, gene set enrichment analysis (GSEA)
of lncRNAs specifically upregulated in the L6E subtype
successfully stratified them (Figure S4C). Furthermore,
we explored the relationship of LNC6 subtypes with
other molecular subtypes reported in previous studies
(Figures 2C-2F).2,3,5,6 The poor prognostic L6F subtype
largely overlapped with the genomically stable, epithelial-
mesenchymal transition (EMT), mesenchymal phenotype,
and invasive subtypes, all of which have been associated
with poor clinical outcome. Enrichment of L6C with the
microsatellite instability (MSI) subtype is well matched
with its negative predictive value for chemotherapy.7 In
line with this, several L6F and L6C-specifc lncRNAs have
previously been associated with poor clinical outcome
and chemoresistance (Supplementary Discussion). Mean-
while, L6B was enriched with the chromosomal instability
and proliferative subtypes, supporting association between
chemosensitivity and proliferative signature. L6E subtype
was 100% Epstein–Barr virus (EBV) subtype, and this
is also in good agreement with favorable prognoses and
response to pembrolizumab inMSI-high and EBV-positive
tumors. Taken together, consideration of the lncRNA
expression pattern may add predictive value for response
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F IGURE 1 Prognostic association of LNC6 subtypes. (A) mRNA expression signature specific to LNC6 subtypes in the TCGA cohort
(n = 258). Subtype-specific mRNA expression signatures were identified using multiple two-class t-tests (p < 0.001), yielding few hundred
genes for each subtype. The top 200 mRNAs were selected for each subtype according to the log ratio. (B) Schematic diagram for prediction
model. Samples in the test cohorts were assigned to one of the six subtypes according to the Bayesian probability scores. (C) Kaplan–Meier
plots with global p-value from log-rank test of overall survival and recurrence-free survival of patients in the test cohorts (n = 1,933). In
pairwise comparisons, the L6C demonstrated significantly shorter overall survival than all the other groups except the L6E, and the L6F
showed significantly shorter recurrence-free survival than the L6B and L6C (adjusted p-value can be found in Table S2
to adjuvant chemotherapy and immune checkpoint
blockade.
Moreover, we carried out bioinformatics analyses and
took advantage of transcriptomic data from other studies
to establish the biological implications of the LNC6 sub-
types. GSEA and ingenuity pathway analysis revealed bio-
logical pathways and regulators characterizing each sub-
type (Figure S5; Table S5; Supplementary Discussion). In
agreement with the activation of pathways associated with
stemness, transcription factors overexpressed during the
early stomach development were upregulated in the L6F
subtype (Figure S6).8 Conversely, S-phase-enriched lncR-
NAs were downregulated in the L6F subtype, supporting
correlation between quiescence and stem-like characteris-
tics (Figure S7).9 Such expression pattern of biological sig-
natures might account for the bad clinical outcome consis-
tently seen in the L6F subtype.
We investigated therapeutic approaches for the L6F
subtype based on gene silencing experiment and phar-
macogenomic analysis. First, we examined expression
level of five L6F subtype-specific lncRNAs in six GC
cell lines using RT-qPCR (primers listed in Table S6).
Based on EMT phenotype characterization in a previ-
ous study,10 the average expression level was higher in
the EMT subtype cell lines for all five lncRNAs, among
which ZNF667-AS1 achieved significance despite small
sample number (Table S7). Then, we tested the functional
association between ZNF667-AS1 andmesenchymal/stem-
like characteristics with knockdown and overexpression
studies (Figures 3A and 3B). Knockdown of ZNF667-AS1
(ENSG00000166770.6) by siRNA in the EMT subtype cell
lines decreased their migratory and invasive activity, as
well as sphere formation under anchorage-independent
growth (Figure 3C). In agreement with this, silencing
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F IGURE 2 Association of LNC6 subtypes with response to chemotherapy and other molecular subtypes. (A and B) Kaplan–Meier plots
of overall survival and recurrence-free survival among patients who received adjuvant chemotherapy (CTX) and those who did not, for L6B
(n = 90), L6C (n = 70), and L6F (n = 112) subtypes. Patients pooled from GSE13861, GSE15459, and GSE26942 with AJCC stage II, III, or IV
disease without distant metastasis were included in the analysis. (C-F) Chord diagram for the LNC6 subtypes and other classifications
corresponding to each cohort. Each chord represents a sample overlapping between the two subtypes. (C) TCGA cohort. (D) GSE62254. (E)
GSE13861 and GSE26942. (F) GSE15459. Abbreviations: CIN, chromosomal instability; EBV, Epstein–Barr virus; EMT, epithelial-mesenchymal
transition; EP, epithelial phenotype; GS, genomically stable; INV, invasive; MET, metabolic; MSI, microsatellite instability; MP, mesenchymal
phenotype; PRO, proliferative
ZNF667-AS1 increased the expression of an epithelial
marker (E-cadherin) and decreased the expression of
mesenchymal markers (N-cadherin and vimentin) (Fig-
ure 4A). Moreover, this increased sensitivity to drugs com-
monly used for GC treatment – oxaliplatin and 5-FU (Fig-
ure 4B). On the other hand, overexpression of ZNF667-AS1
in the non-EMT subtype cell lines induced mesenchymal
marker expression and chemoresistance, while reducing
their epithelial marker expression (Figures 4A and 4B).
In addition, we looked into two independent pharmacoge-
nomic datasets of GC cell lines to identify drugs that could
specifically target the L6F subtype. By performing corre-
lation analysis between drug sensitivity AUC values and
L6F probability from lncRNA expression, we found three
drugs that had negative correlation with significance in
both datasets - YM155, PI-103, and Obatoclax (Figure 4C).
Previous studies reported the selective efficacy of these
drugs against themesenchymal and stem-like GC (Supple-
mentary Discussion). Our study has some limitations - the
retrospective nature of the clinical data and the lack of ani-
mal studies.
In conclusion, we demonstrated clinical implication
of the lncRNA-based stratification and biological asso-
ciation of a specific lncRNA in GC. Significant associa-
tion of lncRNA expression with prognosis and therapeutic
responses indicate that it could be used to elaborate preci-
sion medicine for GC. Moreover, functional association of
a lncRNAwith clinically relevant phenotypes supports the
notion of lncRNA-targeting therapeutics.
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F IGURE 3 Mesenchymal/stem-like phenotypes mediated by ZNF667-AS1, a L6F subtype-specific lncRNA. (A and B) Examination of
ZNF667-AS1 via real-time PCR after transfection of (A) the EMT subtype GC cell lines with siRNA (siNT for non-target; si#2 for ZNF667-AS1)
and (b) the non-EMT subtype GC cell lines with vector (vector only as control; overexpression vector for ZNF667-AS1). (C) Representative
images and results of migration, invasion, and sphere formation assays from siRNA experiment on EMT-subtype GC cell lines. Statistical bar
graphs show the average results from three independent experiments. (t-test, **p < 0.05; n = 3). The microscope images are magnified by *200
and *600
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F IGURE 4 EMT marker expression and drug sensitivities associated with ZNF667-AS1. Drug repurposing approach for the L6F subtype.
(A) Western blot analyses of the indicated EMT marker proteins in siRNA-transfected EMT subtype GC cell lines and vector-transfected
non-EMT subtype GC cell lines. (B) Half maximal inhibitory concentration (IC50) from the MTS assay of oxaliplatin and 5-FU in the
siRNA-transfected EMT subtype GC cell lines or vector-transfected non-EMT subtype GC cell lines. (C) Spearman correlation analysis
between area under the dose-response curve (AUC) values and the L6F probability predicted from lncRNA expression in two independent
pharmacogenomic datasets of GC cell lines. Seven cell lines (Hs746T, SNU1750, MKN1, SK4, SNU484, SNU668, and YCC11) with previously
confirmed mesenchymal phenotypes are classified as the EMT subtype in the Lee et al dataset. Abbreviations: GDSC, The Genomics of Drug
Sensitivity in Cancer Project
8 Department of Biomedical Systems Informatics, Yonsei
University College of Medicine, Seoul, Korea
Correspondence
Jae-Ho Cheong, MD, PhD, Department of Surgery, Yonsei
University College of Medicine, 50 Yonsei-ro,
Seodaemun-gu, Seoul 120–752, Korea.
Email: jhcheong@yuhs.ac
Ju-Seog Lee, PhD, MD, Anderson Cancer Center, 6565
MD Anderson Blvd, Houston, TX 77054, USA.
Email: jlee@mdanderson.org
#Both the authors share the first co-authorship.
KEYWORDS
chemotherapy, gastric cancer, immunotherapy, long non-coding





1. Lee JS, Chu IS, Heo J, et al. Classification and prediction of sur-
vival in hepatocellular carcinoma by gene expression profiling.
Hepatology. 2004;40(3):667–676.
2. Lei Z, Tan IB, Das K, et al. Identification of molecular sub-
types of gastric cancer with different responses to PI3-kinase
inhibitors and 5-fluorouracil. Gastroenterology. 2013;145(3):554–
565.
3. Oh SC, Sohn BH, Cheong JH, et al. Clinical and genomic land-
scape of gastric cancer with a mesenchymal phenotype. Nat
Commun. 2018;9(1):1777.
4. Kim ST, Cristescu R, Bass AJ, et al. Comprehensive molecu-
lar characterization of clinical responses to PD-1 inhibition in
metastatic gastric cancer. Nat Med. 2018;24(9):1449–1458.
6 of 6 LETTER TO EDITOR
5. Cristescu R, Lee J, NebozhynM, et al. Molecular analysis of gas-
tric cancer identifies subtypes associated with distinct clinical
outcomes. Nat Med. 2015;21(5):449–456.
6. Sohn BH, Hwang JE, Jang HJ, et al. Clinical significance of four
molecular subtypes of gastric cancer identified by The Cancer
Genome Atlas Project. Clin Cancer Res. 2017. https://doi.org/10.
1158/1078-0432.CCR-16-2211.
7. Pietrantonio F, Miceli R, Raimondi A, et al. Individual patient
data meta-analysis of the value of microsatellite instability as
a biomarker in gastric cancer. J Clin Oncol. 2019;37(35):3392–
3400.
8. Li X, Zhang C, Gong T, et al. A time-resolved multi-omic atlas
of the developing mouse stomach.Nat Commun. 2018;9(1):4910.
9. Ali MM, Akhade VS, Kosalai ST, et al. PAN-cancer analysis
of S-phase enriched lncRNAs identifies oncogenic drivers and
biomarkers. Nat Commun. 2018;9(1):883.
10. Lee J, Kim H, Lee JE, et al. Selective cytotoxicity of the NAMPT
inhibitor FK866 toward gastric cancer cells with markers of the
epithelial-mesenchymal transition, due to loss of NAPRT. Gas-
troenterology. 2018;155(3):799–814 e713.
SUPPORT ING INFORMATION
Additional supporting information may be found online
in the Supporting Information section at the end of the
article.
